DE NITTO, SIMONE
 Distribuzione geografica
Continente #
NA - Nord America 722
EU - Europa 398
AS - Asia 131
OC - Oceania 4
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.257
Nazione #
US - Stati Uniti d'America 719
CN - Cina 103
IE - Irlanda 87
FR - Francia 77
IT - Italia 71
SE - Svezia 66
DE - Germania 42
FI - Finlandia 21
GB - Regno Unito 15
KR - Corea 11
BE - Belgio 5
VN - Vietnam 5
AU - Australia 3
IR - Iran 3
AT - Austria 2
CA - Canada 2
ES - Italia 2
HK - Hong Kong 2
ID - Indonesia 2
PL - Polonia 2
RU - Federazione Russa 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
EG - Egitto 1
EU - Europa 1
IS - Islanda 1
JP - Giappone 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
UZ - Uzbekistan 1
Totale 1.257
Città #
Chandler 260
Ashburn 85
Dublin 84
Beijing 41
Redmond 37
Lawrence 25
Princeton 25
Sindelfingen 20
Seattle 19
Wilmington 19
Helsinki 16
Verona 15
Seoul 11
Southend 11
Jacksonville 9
Ann Arbor 7
New York 6
Ancona 5
Bonndorf 5
Brussels 5
Lappeenranta 5
Fairfield 4
Peschiera del Garda 4
Rome 4
Washington 4
Woodbridge 4
Dongguan 3
Hangzhou 3
Levallois-perret 3
Milan 3
Neumünster 3
Norwalk 3
Tappahannock 3
Cambridge 2
Chiuppano 2
Dong Ket 2
Frankfurt am Main 2
Fuzhou 2
Haikou 2
Hebei 2
Hong Kong 2
Krakow 2
Madrid 2
Redwood City 2
San Giovanni Lupatoto 2
Shenyang 2
Taiyuan 2
Taizhou 2
Trevenzuolo 2
Turin 2
Vienna 2
Xi'an 2
Ascoli Piceno 1
Auckland 1
Brescia 1
Brisbane 1
Bucharest 1
Cairo 1
Canberra 1
Cassano delle Murge 1
Chicago 1
Clonee 1
Dhaka 1
Dubai 1
Edinburgh 1
Fremont 1
Grafing 1
Guangzhou 1
Gunzenhausen 1
Ho Chi Minh City 1
Jiaxing 1
Jinan 1
Kemerovo 1
Las Vegas 1
Laurel 1
London 1
Los Angeles 1
Lviv 1
Manila 1
Marino 1
Melbourne 1
Monte Carasso 1
Montignoso 1
Montréal 1
Nanjing 1
Negrar 1
Newark 1
Novokuznetsk 1
Padova 1
Palermo 1
Pieve di Soligo 1
Piscataway 1
Reykjavik 1
San Francisco 1
San Mateo 1
Segrate 1
Shenzhen 1
Surabaya 1
Tashkent 1
Tianjin 1
Totale 837
Nome #
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 64
Thrombin Generation in Patients with Coronavirus Disease 2019 60
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 58
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 53
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 52
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 52
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 52
Bile Acids Quantification by Liquid Chromatography-Tandem Mass Spectrometry: Method Validation, Reference Range, and Interference Study 49
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 49
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 48
Preliminary evaluation of Roche Cobas Elecsys Anti-SARS-CoV-2 chemiluminescence immunoassay 47
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 46
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 46
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 44
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 42
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 42
Impact of water temperature on reconstitution of quality controls for routine hemostasis testing 37
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 37
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 35
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 33
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 32
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 30
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 28
Machine learning model comparison in the screening of cholangiocarcinoma using plasma bile acids profiles 25
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 22
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 22
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 21
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 17
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 16
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 16
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 15
Monoclonal gammopathy in SARS-CoV-2 infection 13
Cellular immunity against SARS-CoV-2 depends on the serological status 13
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 12
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 12
Impact of the COVID-19 pandemic on the volume of laboratory testing 12
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 11
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 10
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 10
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 9
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 9
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 9
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 9
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 7
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 6
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 5
Totale 1.337
Categoria #
all - tutte 7.071
article - articoli 7.071
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.142


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 0 0 0 0 1 1 0 1 1
2020/202181 11 1 1 4 9 5 10 2 3 3 5 27
2021/2022228 31 44 7 9 12 7 5 7 17 7 27 55
2022/2023659 37 55 58 120 37 138 23 59 67 9 30 26
2023/2024365 20 30 19 46 61 50 44 64 3 22 6 0
Totale 1.337